Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2007 Apr 15:7:65.
doi: 10.1186/1471-2407-7-65.

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer

Riccardo Samaritani  1 , Giacomo Corrado, Enrico Vizza, Carlo Sbiroli
Affiliations
Case Reports

Cyclophosphamide "metronomic" chemotherapy for palliative treatment of a young patient with advanced epithelial ovarian cancer

Riccardo Samaritani et al. BMC Cancer. .

Abstract

Background: Evaluation of the clinical efficacy and tolerance of metronomic chemotherapy as salvage therapy in a young patient with advanced, platinum resistant, ovarian carcinoma and bad performance status.

Case presentation: We tried palliative chemotherapy with daily low dose oral cyclophosphamide with a patient suffering from stage IIIC ovarian cancer that responded to daily cyclophosphamide (CTX) after no response to chemotherapy with paclitaxel and carboplatin as first line and progression after second line with topotecan. The progression-free survival time on daily low dose oral cyclophosphamide treatment was 65 months without side effects. She was well during the chemotherapy and lived a normal working and social life.

Conclusion: We think that use of low dose of oral CTX should be investigated further as a strategy against tumour progression after standard chemotherapy in patients who are platinum resistant with poor performance status.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Computer tomography (CT) scan of advanced ovarian cancer before treatment showing conglomeration of the bowel.
Figure 2
Figure 2
Computer tomography (CT) scan of advanced ovarian cancer after 65 months after diagnosis showing stable disease without bowel occlusion due to successful colostomy.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sood AK, Abu-Rustum NR, Barakat RR, Bodurka DC, Brown J, Donato ML, Poynor EA, Wolf JK, Gershenson DM. Fifth International Conference on Ovarian Cancer: challenges and opportunities. Gynecol Oncol. 2005;97:916–923. doi: 10.1016/j.ygyno.2005.03.013. - DOI - PubMed
    1. Eltabbakh GH. Recent advances in the management of women with ovarian cancer. Minerva Ginecol. 2004;56:81–89. - PubMed
    1. Latorre A, De Lena M, Catino A, Crucitta E, Sambiasi D, Guida M, Misino A, Lorusso V. Epithelial ovarian cancer: second andthird line chemotherapy. Int J Oncol. 2002;21:179–186. - PubMed
    1. Gasparini G. Metronomic scheduling: the future of chemotherapy? Lancet Oncol. 2001;2:733–740. doi: 10.1016/S1470-2045(01)00587-3. - DOI - PubMed
    1. Kerbel RS, Klement G, Pritchard KI, Kamen BA. Continuous low-dose anti-angiogenic (metronomic) chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol. 2002;13:12–15. doi: 10.1093/annonc/mdf093. - DOI - PubMed

Publication types

MeSH terms